8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 9, 2026·SEC
ImmunityBio, Inc.(IBRX)Earnings, Financials & Key Ratios
IBRX•NASDAQ
Price updated Jun 19, 2026
AboutImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.Show more
- Revenue$113M+668.3%
- EBITDA-$241M+26.4%
- Net Income-$351M+15.0%
- EPS (Diluted)-0.38+38.7%
- Gross Margin99.34%-0.7%
- EBITDA Margin-212.29%+90.4%
- Operating Margin-226%+90.3%
- Net Margin-310.18%+88.9%
IBRX Key Insights
ImmunityBio, Inc. (IBRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Strong 5Y sales CAGR of 184.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 31.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IBRX Price & Volume
ImmunityBio, Inc. (IBRX) stock price & volume — 10-year historical chart
Loading chart...
IBRX Growth Metrics
ImmunityBio, Inc. (IBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years85.41%
5 Years184.76%
3 Years678.62%
TTM351.53%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-108.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-52.43%
Return on Capital
10 Years-111.47%
5 Years-157.42%
3 Years-130.35%
Last Year-66.66%
IBRX Recent Earnings
ImmunityBio, Inc. (IBRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.09-12.5%
$0.08
Rev
$44M+2.6%
$43M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$0.06+25.0%
$0.08
Rev
$38M-0.2%
$38M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.07+30.0%
$0.10
Rev
$32M-15.1%
$38M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.10+0.0%
$0.10
Rev
$26M-17.1%
$32M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.09vs $0.08-12.5% | $44Mvs $43M+2.6% |
| Q1 2026 | Feb 23, 2026 | $0.06vs $0.08+25.0% | $38Mvs $38M-0.2% |
| Q4 2025 | Nov 4, 2025 | $0.07vs $0.10+30.0% | $32Mvs $38M-15.1% |
| Q3 2025 | Aug 5, 2025 | $0.10vs $0.10+0.0% | $26Mvs $32M-17.1% |
Based on last 12 quarters of dataView full earnings history →
IBRX Peer Comparison
ImmunityBio, Inc. (IBRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 NKGN | 3.08M | 0.06 | -0.04 | -36.13% | ||||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% |
Compare IBRX vs Peers
ImmunityBio, Inc. (IBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IBRX Income Statement
ImmunityBio, Inc. (IBRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 45K | 47K | 43K | 605K | 934K | 240K | 622K | 14.74M | 113.29M | 140.98M |
Revenue Growth % | 2.27% | 4.44% | -8.51% | 1306.98% | 54.38% | -74.3% | 159.17% | 2270.58% | 668.31% | 351.53% |
Cost of Goods Sold | 0 | -3.11M | 9.01M | 0 | 0 | 0 | 0 | 0 | 753K | 8.75M |
COGS % of Revenue | - | -6617.02% | 20958.14% | - | - | - | - | - | 0.66% | - |
Gross Profit | 45K▲ 0% | 3.16M▲ 6915.6% | -8.97M▼ 384.1% | 605K▲ 106.7% | 934K▲ 54.4% | 240K▼ 74.3% | 622K▲ 159.2% | 14.74M▲ 2270.6% | 112.53M▲ 663.2% | 132.23M▲ 0% |
Gross Margin % | 100% | 6717.02% | -20858.14% | 100% | 100% | 100% | 100% | 100% | 99.34% | 93.79% |
Gross Profit Growth % | 2.27% | 6915.56% | -384.1% | 106.75% | 54.38% | -74.3% | 159.17% | 2270.58% | 663.21% | - |
Operating Expenses | 93.6M | 88.88M | 57.94M | 221.49M | 331.21M | 351.54M | 362.87M | 358.93M | 368.56M | 393.62M |
OpEx % of Revenue | 207997.78% | 189108.51% | 134739.53% | 36609.09% | 35461.88% | 146474.17% | 58339.55% | 2434.23% | 325.33% | - |
Selling, General & Admin | 53.82M | 35.46M | 9.05M | 71.32M | 135.26M | 102.71M | 129.62M | 168.78M | 147.18M | 157.46M |
SG&A % of Revenue | 119602.22% | 75453.19% | 21053.49% | 11788.1% | 14481.37% | 42795% | 20839.23% | 1144.68% | 129.92% | - |
Research & Development | 39.78M | 53.42M | 48.88M | 139.51M | 195.96M | 248.15M | 232.37M | 190.14M | 207.88M | 231.55M |
R&D % of Revenue | 88395.56% | 113655.32% | 113686.05% | 23059.01% | 20980.51% | 103395.42% | 37357.88% | 1289.55% | 183.49% | - |
Other Operating Expenses | 0 | 0 | 0 | 10.66M | 0 | 681K | 886K | 0 | 13.51M | 1000K |
Operating Income | -99.12M▲ 0% | -98.39M▲ 0.7% | -66.91M▲ 32.0% | -220.88M▼ 230.1% | -330.28M▼ 49.5% | -351.3M▼ 6.4% | -362.25M▼ 3.1% | -344.18M▲ 5.0% | -256.03M▲ 25.6% | -261.39M▲ 0% |
Operating Margin % | -220266.67% | -209338.3% | -155597.67% | -36509.09% | -35361.88% | -146374.17% | -58239.55% | -2334.23% | -226% | -185.41% |
Operating Income Growth % | 20.39% | 0.74% | 32% | -230.13% | -49.53% | -6.36% | -3.12% | 4.99% | 25.61% | - |
EBITDA | -93.55M | -88.83M | -57.9M | -208.14M | -316.04M | -333.04M | -343.74M | -326.63M | -240.5M | -245.31M |
EBITDA Margin % | -207897.78% | -189008.51% | -134639.53% | -34403.47% | -33837.47% | -138765.83% | -55263.34% | -2215.18% | -212.29% | -174.01% |
EBITDA Growth % | 22.61% | 5.05% | 34.83% | -259.51% | -51.84% | -5.38% | -3.21% | 4.98% | 26.37% | 17.29% |
D&A (Non-Cash Add-back) | 5.57M | 9.55M | 9.01M | 12.74M | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M | 16.08M |
EBIT | -96.3M | -96.3M | -65.87M | -216.96M | -334.99M | -370.14M | -497.18M | -281.99M | -239.08M | -207.84M |
Net Interest Income | 0 | 0 | -3.16M | -7.35M | -14.01M | -44.44M | -85.85M | -129.26M | -105.83M | -103.63M |
Interest Income | 0 | 0 | 2.76M | 1.73M | 836K | 2.71M | 863K | 2.4M | 6.7M | 8.5M |
Interest Expense | 618K | 433K | 5.92M | 9.07M | 14.85M | 47.15M | 86.72M | 131.66M | 112.53M | 112.12M |
Other Income/Expense | 2.2M | 1.66M | 1.02M | -5.15M | -19.56M | -65.99M | -221.64M | -69.46M | -95.58M | -593.11M |
Pretax Income | -96.92M▲ 0% | -96.73M▲ 0.2% | -65.89M▲ 31.9% | -226.03M▼ 243.1% | -349.84M▼ 54.8% | -417.29M▼ 19.3% | -583.89M▼ 39.9% | -413.64M▲ 29.2% | -351.61M▲ 15.0% | -854.5M▲ 0% |
Pretax Margin % | -215368.89% | -205806.38% | -153223.25% | -37360.83% | -37456% | -173869.17% | -93873.31% | -2805.32% | -310.37% | -606.13% |
Income Tax | -493K | -503K | -97K | -1.85M | 9K | 34K | -40K | 0 | -135K | 90K |
Effective Tax Rate % | 0.51% | 0.52% | 0.15% | 0.82% | -0% | -0.01% | 0.01% | 0% | 0.04% | -0.01% |
Net Income | -96.42M▲ 0% | -96.23M▲ 0.2% | -65.79M▲ 31.6% | -221.85M▼ 237.2% | -346.79M▼ 56.3% | -416.57M▼ 20.1% | -583.2M▼ 40.0% | -413.56M▲ 29.1% | -351.4M▲ 15.0% | -854.53M▲ 0% |
Net Margin % | -214273.33% | -204736.17% | -152997.67% | -36669.59% | -37129.55% | -173569.58% | -93761.41% | -2804.77% | -310.18% | -606.15% |
Net Income Growth % | 20.19% | 0.2% | 31.63% | -237.22% | -56.32% | -20.12% | -40% | 29.09% | 15.03% | -108.88% |
Net Income (Continuing) | -96.42M | -96.23M | -65.79M | -224.19M | -349.85M | -417.32M | -583.85M | -413.64M | -351.47M | -854.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -12.32M | 0 | 1.32M | -1.74M | -2.49M | 1.05M | 969K | 895K | 880K |
EPS (Diluted) | -0.30▲ 0% | -0.30▲ 0.0% | -0.42▼ 40.0% | -0.59▼ 40.5% | -0.89▼ 50.8% | -1.04▼ 16.9% | -1.15▼ 10.6% | -0.62▲ 46.1% | -0.38▲ 38.7% | -0.83▲ 0% |
EPS Growth % | 18.92% | 0% | -40% | -40.48% | -50.85% | -16.85% | -10.58% | 46.09% | 38.71% | -52.43% |
EPS (Basic) | -0.30 | -0.30 | -0.42 | -0.59 | -0.89 | -1.04 | -1.15 | -0.59 | -0.38 | - |
Diluted Shares Outstanding | 316.15M | 325.05M | 383.18M | 383.18M | 389.23M | 399.9M | 508.64M | 700.44M | 919.86M | 1.03B |
Basic Shares Outstanding | 316.15M | 325.05M | 383.18M | 383.18M | 389.23M | 399.9M | 508.64M | 697.31M | 919.86M | 1.03B |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IBRX Balance Sheet
ImmunityBio, Inc. (IBRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 132.46M | 88.77M | 55.76M | 111.71M | 334.35M | 140.58M | 294.08M | 184.59M | 314.88M | 452.95M |
Cash & Short-Term Investments | 128.15M | 74.15M | 51.65M | 96.06M | 317.12M | 107.18M | 266.46M | 149.81M | 242.82M | 380.88M |
Cash Only | 23.87M | 16.82M | 15.51M | 34.91M | 181.1M | 104.64M | 265.45M | 143.43M | 88.33M | 205.19M |
Short-Term Investments | 104.28M | 57.33M | 36.14M | 61.15M | 136.01M | 2.54M | 1.01M | 6.38M | 154.48M | 175.69M |
Accounts Receivable | 1.26M | 12.17M | 303K | 2M | 1.33M | 1.89M | 3.17M | 2.65M | 42.62M | 43.27M |
Days Sales Outstanding | 10.2K | 94.5K | 2.57K | 1.21K | 520.93 | 2.87K | 1.86K | 65.67 | 137.31 | 90.78 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.27M | 910K | 547K |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | 441.1 | 74.96 |
Other Current Assets | 880K | 42K | 24K | 0 | 2.96M | 2.9M | 5.21M | 1.3M | 3.89M | 3.91M |
Total Non-Current Assets | 117.98M | 93.18M | 87.37M | 109.67M | 134.56M | 221.78M | 210.37M | 198.35M | 187.02M | 193.68M |
Property, Plant & Equipment | 76.73M | 76.89M | 72.23M | 90.68M | 119.17M | 189.45M | 182.68M | 170.46M | 147.54M | 146.07M |
Fixed Asset Turnover | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.09x | 0.77x | 1.22x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 910K | 910K |
Intangible Assets | 2.83M | 12.09M | 0 | 1.46M | 1.42M | 20M | 17.09M | 15.93M | 13.04M | 11.97M |
Long-Term Investments | 38.28M | 14.38M | 10.93M | 11.4M | 7.6M | 840K | 891K | 0 | 10.48M | 28.5M |
Other Non-Current Assets | 151K | -1.67M | 4.21M | 6.13M | 6.38M | 11.49M | 9.7M | 11.96M | 15.04M | 24.72M |
Total Assets | 250.44M▲ 0% | 181.95M▼ 27.3% | 143.12M▼ 21.3% | 221.38M▲ 54.7% | 468.91M▲ 111.8% | 362.36M▼ 22.7% | 504.45M▲ 39.2% | 382.93M▼ 24.1% | 501.9M▲ 31.1% | 646.64M▲ 0% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.04x | 0.23x | 0.27x |
Asset Growth % | -21.12% | -27.35% | -21.34% | 54.68% | 111.81% | -22.72% | 39.21% | -24.09% | 31.07% | 176.79% |
Total Current Liabilities | 20.87M | 27.26M | 11.56M | 68.13M | 369M | 500.86M | 58.28M | 54.94M | 61.75M | 67.95M |
Accounts Payable | 5.87M | 2.79M | 1.75M | 11.51M | 11.42M | 21.02M | 9.2M | 6.72M | 6.98M | 11.19M |
Days Payables Outstanding | - | -327.8 | 70.84 | - | - | - | - | - | 3.38K | 327.1 |
Short-Term Debt | 618K | 965K | 3.96M | 0 | 299.24M | 431.9M | 0 | 0 | 9.29M | 8.56M |
Deferred Revenue (Current) | 520K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13.87M | 23.5M | 4.78M | 18M | 16.52M | 19.74M | 18.31M | 15.98M | 25.42M | 36.94M |
Current Ratio | 6.35x | 3.26x | 4.82x | 1.64x | 0.91x | 0.28x | 5.05x | 3.36x | 5.10x | 6.67x |
Quick Ratio | 6.35x | 3.26x | 4.82x | 1.64x | 0.91x | 0.28x | 5.05x | 3.21x | 5.08x | 6.66x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -2.8K | -161.36 |
Total Non-Current Liabilities | 10.73M | 8.68M | 10.88M | 271.74M | 343.83M | 311.31M | 1.03B | 816.12M | 939.72M | 1.45B |
Long-Term Debt | 0 | 0 | 0 | 254.35M | 306.35M | 241.27M | 681.54M | 461.88M | 835.15M | 1.08B |
Capital Lease Obligations | 6.65M | 5.95M | 10.88M | 16.18M | 37.07M | 47.95M | 39.94M | 34.82M | 33.67M | 137.25M |
Deferred Tax Liabilities | 498K | 0 | 0 | 170K | 162K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.41M | 2.74M | 0 | 1.03M | 249K | 22.09M | 310.63M | 319.42M | 70.89M | 331.77M |
Total Liabilities | 31.6M | 35.94M | 22.44M | 339.87M | 712.82M | 812.18M | 1.09B | 871.06M | 1B | 1.52B |
Total Debt | 7.27M | 6.91M | 14.85M | 275.55M | 645.66M | 723.77M | 726.72M | 504.17M | 878.12M | 1.12B |
Net Debt | -16.6M | -9.91M | -660K | 240.63M | 464.56M | 619.13M | 461.27M | 360.74M | 789.78M | 919.41M |
Debt / Equity | 0.03x | 0.05x | 0.12x | - | - | - | - | - | - | -1.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.58x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.75x |
Interest Coverage | -155.82x | -222.39x | -11.13x | -23.91x | -22.56x | -7.85x | -5.73x | -2.14x | -2.12x | -1.85x |
Total Equity | 218.84M▲ 0% | 133.69M▼ 38.9% | 120.68M▼ 9.7% | -118.49M▼ 198.2% | -243.91M▼ 105.9% | -449.82M▼ 84.4% | -585.94M▼ 30.3% | -488.13M▲ 16.7% | -499.57M▼ 2.3% | -869.13M▲ 0% |
Equity Growth % | -25.42% | -38.91% | -9.73% | -198.19% | -105.85% | -84.42% | -30.26% | 16.69% | -2.34% | -1.58% |
Book Value per Share | 0.69 | 0.41 | 0.31 | -0.31 | -0.63 | -1.12 | -1.15 | -0.70 | -0.54 | -0.85 |
Total Shareholders' Equity | 218.84M | 146.01M | 120.68M | -119.81M | -242.17M | -447.33M | -586.99M | -489.1M | -499.57M | -870.01M |
Common Stock | 8K | 8K | 10K | 38K | 40K | 42K | 67K | 85K | 101K | 104K |
Retained Earnings | -498.71M | -594.98M | -662.19M | -1.62B | -1.96B | -2.38B | -2.96B | -3.38B | -3.73B | -4.36B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -381K | -267K | -105K | 122K | 4K | 183K | 10K | 1.2M | 28.96M | 27.45M |
Minority Interest | 0 | -12.32M | 0 | 1.32M | -1.74M | -2.49M | 1.05M | 969K | 895K | 880K |
IBRX Cash Flow Statement
ImmunityBio, Inc. (IBRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -48.78M | -63.38M | -152.11M | -171.72M | -274.42M | -337.51M | -366.76M | -391.24M | -304.94M | -294.39M |
Operating CF Margin % | -108400% | -134853.19% | -353741.86% | -28384.13% | -29381.05% | -140628.75% | -58964.15% | -2653.35% | -269.17% | - |
Operating CF Growth % | -26.4% | -29.93% | -139.99% | -12.9% | -59.8% | -22.99% | -8.67% | -6.67% | 22.06% | 80.38% |
Net Income | -96.42M | -96.23M | -160.16M | -224.19M | -346.79M | -416.57M | -583.85M | -413.64M | 0 | -854.53M |
Depreciation & Amortization | 5.57M | 9.55M | 14.04M | 12.74M | 14.3M | 34.54M | 18.51M | 17.55M | 0 | 8.26M |
Stock-Based Compensation | 37M | 2.04M | 3.42M | 2.19M | 57.18M | 40.18M | 49.16M | 34.43M | 0 | 9.65M |
Deferred Taxes | -497K | -498K | -8K | -2.94M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 50.33M | 44.55M | 6.23M | 24.11M | 16.29M | 20.34M | 145.44M | -10.15M | -250.61M | 500.75M |
Working Capital Changes | 3.23M | -554K | -15.64M | 16.36M | -15.39M | -16M | 3.98M | -19.42M | -54.33M | -20.46M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.36M | -40.21M | -16.35M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.27M | -6.33M | -11.07M |
Change in Payables | 150K | -1.1M | 1.19M | 2.57M | 0 | 0 | -6.48M | -3.17M | -190K | -1.34M |
Cash from Investing | 99.55M | 57.1M | 18.55M | -19.81M | -84.89M | 27.3M | -30.47M | -12.25M | -149.8M | -185.58M |
Capital Expenditures | -34.81M | -13.1M | -4.29M | -1.67M | -33.56M | -78.16M | -30.58M | -6.89M | -4.25M | -4.14M |
CapEx % of Revenue | 77366.67% | 27876.6% | 9969.77% | 275.87% | 3593.47% | 32567.5% | 4917.04% | 46.71% | 3.75% | 2.94% |
Acquisitions | -32K | 412K | 200K | 8K | 0 | 0 | 0 | -1M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 32K | 35.03M | -2.5M | -8K | -51.32M | 105.46M | 0 | -747K | 0 | -181.36M |
Cash from Financing | -34.98M | -771K | 114.28M | 150.68M | 505.44M | 233.61M | 558.34M | 281.63M | 400.24M | 625.15M |
Debt Issued (Net) | -19.93M | -477K | 47.67M | 63.7M | 338.5M | 174.07M | 258.62M | 96.89M | 1.72M | 1.78M |
Equity Issued (Net) | -14.01M | -171K | 27.5M | 86.3M | -4.06M | -616K | 110.1M | 111.36M | 400.78M | 458.62M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -15.23M | -228K | -2.5M | 0 | -4.06M | -616K | 0 | 0 | 0 | 0 |
Other Financing | -1.04M | -123K | 39.11M | 673K | 171.01M | 60.16M | 189.62M | 73.38M | -2.27M | 164.75M |
Net Change in Cash | 15.79M▲ 0% | -7.05M▼ 144.7% | -19.3M▼ 173.7% | -40.89M▼ 111.9% | 146.19M▲ 457.5% | -76.31M▼ 152.2% | 160.82M▲ 310.7% | -121.88M▼ 175.8% | -54.48M▲ 55.3% | 145.15M▲ 0% |
Free Cash Flow | -83.59M▲ 0% | -76.48M▲ 8.5% | -156.4M▼ 104.5% | -173.39M▼ 10.9% | -307.98M▼ 77.6% | -415.67M▼ 35.0% | -397.34M▲ 4.4% | -398.12M▼ 0.2% | -308.78M▲ 22.4% | -298.9M▲ 0% |
FCF Margin % | -185766.67% | -162729.79% | -363711.63% | -28660% | -32974.52% | -173196.25% | -63881.19% | -2700.06% | -272.56% | -212.02% |
FCF Growth % | -85.14% | 8.51% | -104.48% | -10.87% | -77.62% | -34.97% | 4.41% | -0.2% | 22.44% | 20.7% |
FCF per Share | -0.26 | -0.24 | -0.41 | -0.45 | -0.79 | -1.04 | -0.78 | -0.57 | -0.34 | -0.29 |
FCF Conversion (FCF/Net Income) | 0.51x | 0.66x | 2.31x | 0.77x | 0.79x | 0.81x | 0.63x | 0.95x | 0.87x | 0.35x |
Interest Paid | 0 | 0 | 19K | 40K | 2.11M | 35.44M | 77.19M | 92.32M | 0 | 18.86M |
Taxes Paid | 0 | 0 | 3K | 8K | 0 | 0 | 8K | 15K | 0 | 0 |
IBRX Key Ratios
ImmunityBio, Inc. (IBRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -37.65% | -54.59% | -51.73% | -20269.62% | - | - | - | - | - | 138.84% |
Return on Invested Capital (ROIC) | -29.99% | -45.27% | -41.17% | -136.82% | -144.53% | -135.13% | -1217.1% | - | -235.87% | -617.78% |
Gross Margin | 100% | 6717.02% | -20858.14% | 100% | 100% | 100% | 100% | 100% | 99.34% | 93.79% |
Net Margin | -214273.33% | -204736.17% | -152997.67% | -36669.59% | -37129.55% | -173569.58% | -93761.41% | -2804.77% | -310.18% | -606.15% |
Debt / Equity | 0.03x | 0.05x | 0.12x | - | - | - | - | - | - | -1.29x |
Interest Coverage | -155.82x | -222.39x | -11.13x | -23.91x | -22.56x | -7.85x | -5.73x | -2.14x | -2.12x | -1.85x |
FCF Conversion | 0.51x | 0.66x | 2.31x | 0.77x | 0.79x | 0.81x | 0.63x | 0.95x | 0.87x | 0.35x |
Revenue Growth | 2.27% | 4.44% | -8.51% | 1306.98% | 54.38% | -74.3% | 159.17% | 2270.58% | 668.31% | 351.53% |
Related:IBRX Dividend History·IBRX Revenue History·IBRX Price History·IBRX P/E History·IBRX Financial Ratios·IBRX Institutional Holders
IBRX SEC Filings & Documents
ImmunityBio, Inc. (IBRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
IBRX Frequently Asked Questions
ImmunityBio, Inc. (IBRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ImmunityBio, Inc. (IBRX) reported $141.0M in revenue for fiscal year 2025. This represents a 23396% increase from $0.6M in 2013.
ImmunityBio, Inc. (IBRX) grew revenue by 668.3% over the past year. This is strong growth.
ImmunityBio, Inc. (IBRX) reported a net loss of $854.5M for fiscal year 2025.
Dividend & Returns
ImmunityBio, Inc. (IBRX) had negative free cash flow of $298.9M in fiscal year 2025, likely due to heavy capital investments.